Patent SG-11201804673W-A (SG)
Title: Novel anti-claudin antibodies and methods of use
Inventor: FONG SARAH
IPC: C07K16/30
Filed: 2016-12-02
Abstract: International Patent Classification: A.; 3000 Monterey Street, San Mateo, California 94403 C07K 16/30 (2006.01) A61K 45/06 (2006.01) (US). CO7D 519/00 (2006.01) A61K 47/48 (2006.01) A61K 31/55 (2006.01) A61P 35/02 (2006.01) (74) Agents: MEIGS, Julie Broadus et al.; Womble Carlyle Sandridge & Rice, LLP, P.O. Box 7037, Atlanta, Georgia (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau 111111111M 11111111111111111111111111111111111111111111111111111111111111R111111111111111 (10) International Publication Number WO 2017/096163 Al WIPO I PCT (43) International Publication Date 8 June 2017 (08.06.2017) 30357 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (21) International Application Number: PCT/US2016/064617 (22) International Filing Date: 2 December 2016 (02.12.2016) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/263,542 4 December 2015 (04.12.2015) US 62/427,027 28 November 2016 (28.11.2016) US (71) Applicant: ABBVIE STEMCENTRX LLC [US/US]; 1 North Waukegan Road, North Chicago, Illinois 60064 (US). (72) Inventors: FONG, Sarah; 4432 39th Avenue, Oakland, California 94619 (US). SISODIYA, Viltram Natwarsin- hji; 3615 22nd Street, Apt 23, San Francisco, California 94114 (US). STULL, Robert A.; 1519 Fifth Street, Alameda, California 94501 (US). WILLIAMS, Samuel (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, [Continued on next page] (54) Title: NOVEL ANTI-CLAUDIN ANTIBODIES AND METHODS OF USE Alignment of human CLDN6 and CLDN9 protein sequences (57) : Provided herein are nov- el anti-CLDN antibodies and antibody drug conjugates (ADC), including deriv- atives thereof, and methods of using the same to treat proliferative disorders. 1 60 CLDN6 masagmq ILGVVLTLLGWVNGLVSCALPMWEVTAFIGNSIVVAQVVWEGLWMSCVVQSTG III 1 H 1 III 1111111 1111111111111111111111111111111 CLDN9 mastgle LLGMTLAVLGWLGTLVSCALP LWKVTAFIGNSIVVAQVVWEGLWMSCVVQSTG 61 120 CLDN6 QMQCKVYDSLLALPQDLQAAF LOVIALLVALEGLLVYLAGAkcttcveekdskar VLT 111111111111111111111 11111111 II 1111 11 111111 111 III CLDN9 QMQCKVYDSLLALPQDLQAAF LCVIALLLALLGLLVAITGAgcttcvedegakarIVLT 121 180 CLDN6 SGIVFVISGVLTLIPV WTAHAI IRDFYNPLVAEAQKREI GASLYLGWAASGLLLLGGGL 1 1 1 1111 1111111 1111111111 1111 1111111111 11 11111 CLDN9 AGVILLLAGILVLIPV WTAHAI IQDFYNPLVAEALKREI GASLYLGWAAAALLMLCGGL 181 220 CLDN6 lcctcpsggsqgpshymarystsapaisrgpseyptknyv (SEQ ID NO: 10) 111111 I I I I I II 11 CLDN9 lcctcpppgverprg--prlgys±psrs-gasgldkrdyv (SEQ ID NO: 11) W O 20 17 /096 163 Al 217 FIG. 1B WO 2017/096163 Al MIDEDIt01111101011110E11 0ME11111111111111111111111111111111111111 SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, Published: GW, KM, ML, MR, NE, SN, TD, TG). with international search report (Art 21(3)) Declarations under Rule 4.17: before the expiration of the time limit for amending the as to applicant's entitlement to apply for and be granted claims and to be republished in the event of receipt of a patent (Rule 4. 17(ii)) amendments (Rule 48.2(h)) as to the applicant's entitlement to claim the priority of — with sequence listing part of description (Rule 5.2(a)) the earlier application (Rule 4.17(iii))